Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | F2R | P25116 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 2/20 | 0.30 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30441232 | 0.92 | VNN1 (0.35) | DPP4 | |
| SCHEMBL5127466 | 0.91 | JAK1 (0.33) | KDM4EALDH1A1F2RJAK2 | |
| SCHEMBL16416429 | 0.91 | JAK1 (0.33) | KDM4EALDH1A1F2RJAK2 | |
| SCHEMBL4666715 | 0.91 | JAK1 (0.33) | KDM4EALDH1A1F2RJAK2 | |
| SCHEMBL18693201 | 0.89 | CHRM1 (0.39) | — | |
| SCHEMBL18825153 | 0.83 | L3MBTL3 (0.44) | — | |
| SCHEMBL27948 | 0.81 | — | — | |
| SCHEMBL1700820 | 0.80 | GAA (0.35) | KDM4EALDH1A1F2RJAK2GAA | |
| SCHEMBL2707285 | 0.80 | ALDH1A1 (0.34) | KDM4EALDH1A1F2RJAK2SPR | |
| SCHEMBL6107767 | 0.80 | EPHX2 (0.43) | KDM4EDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568959-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| CN-114773256-B | Synthesis method of 4-cyano piperidine | 中国农业大学 | 2024-05-03 | — | — | CN | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| CN-113227068-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023067355-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023053008-A1 | OXIMES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | KEMPHARM DENMARK A/S (DK) | 2023-04-06 | — | — | WO | disclosed |
| WO-2022250069-A1 | SULFUR-CONTAINING PYRAZOLE COMPOUND AND NOXIOUS ORGANISM CONTROL AGENT INCLUDING SULFUR-CONTAINING PYRAZOLE COMPOUND AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2022-12-01 | — | — | WO | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| CN-114773256-A | Synthetic method of 4-cyanopiperidine | 中国农业大学 | 2022-07-22 | — | — | CN | disclosed |
| WO-2006066948-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060069088-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1615699-A2 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | Merck & Co., Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005107469-A2 | MORPHOLINYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-1480972-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004092124-A2 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2003068760-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| US-6518284-B2 | For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary | FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) | 2003-02-11 | — | — | US | disclosed |
| US-20020038031-A1 | New 4 - substituted piperidines | ORJALES VENERO AURELIO (ES) | 2002-03-28 | — | — | US | disclosed |
| EP-1002794-A1 | 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors | FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) | 2000-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069088-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | CCR1, CCR2, CCRL2 | KDM4E 3926/4885ALDH1A1 2799/4885F2R 182/4885 |
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | KDM4E 4275/4885ALDH1A1 3733/4885F2R 38/4885 |
| US-20020038031-A1 | New 4 - substituted piperidines | ADRA2C, ADRB2, ADRB1 | KDM4E 2707/4885ALDH1A1 273/4885F2R 2372/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | KDM4E 4275/4885ALDH1A1 3733/4885F2R 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.